1 day Ago By Defense World Staff
Certara, Inc. (NASDAQ:CERT – Get Free Report) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company.
The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $15.17. Several research firms have recently weighed in on CERT.
Barclays lowered their price objective on Certara from $13.00 to $11.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th.
Robert W. Baird lifted their price objective on shares of Certara from $9.00 to $13.
00 and gave the company a “neutral” rating in a report on Friday, April 11th. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Stephens reiterated an “overweight” rating and set a $17.
00 price target on shares of Certara in a research note on Thursday, February 27th. Finally, TD Cowen initiated coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.
00 price objective for the company.View Our Latest Report on CertaraCertara Trading Up 4.6 %CERT opened at $14.
15 on Friday. The stock has a market cap of $2.28 billion, a PE ratio of -70.
75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64.
The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.
28. Certara has a twelve month low of $8.64 and a twelve month high of $17.
94. The company has a fifty day moving average of $11.62 and a 200-day moving average of $11.
44. Hedge Funds Weigh In On CertaraA number of hedge funds and other institutional investors have recently modified their holdings of the business. Versant Capital Management Inc boosted its position in Certara by 218.
8% in the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after purchasing an additional 1,866 shares during the last quarter. Venturi Wealth Management LLC grew its position in Certara by 839.
1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after buying an additional 2,509 shares during the period. Wells Fargo & Company MN increased its holdings in Certara by 48.
4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after buying an additional 1,047 shares during the last quarter. Johnson Financial Group Inc.
bought a new stake in Certara in the fourth quarter worth about $47,000. Finally, Blue Trust Inc. boosted its stake in Certara by 20.
9% in the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after acquiring an additional 822 shares during the last quarter.
Hedge funds and other institutional investors own 73.96% of the company’s stock. Certara Company Profile (Get Free ReportCertara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally.
It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.Read MoreFive stocks we like better than CertaraFollowing Congress Stock TradesTariff Exemptions Set the Stage for a Taiwan Semiconductor RallyWhat Investors Need to Know About Upcoming IPOsMitigating Tariffs: 3 Stocks to Gain From a Weaker U.S.
DollarWhat is a buyback in stocks? A comprehensive guide for investorsBroadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk.
